Nature of Business - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($) segment dose orphan_drug_designation product	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments | segment	1
Number of vaccination dose regimen | dose	2
Vaccination dose regimen, duration apart	28 days
Modifier gene therapy platform, number of products | product	1
Number of ODDs received (orphan drug designation) | orphan_drug_designation	4
Net loss	$ 18,019	$ 7,077
Accumulated deficit	149,686		$ 131,667
Cash, cash equivalents and restricted cash	$ 129,922	$ 44,943	$ 95,109	$ 24,190